Translate page

English English
en Englishbg Bulgarianzh-CN Chinese (Simplified)hr Croatiancs Czechda Danishnl Dutchfi Finnishfr Frenchde Germanel Greekiw Hebrewhi Hindiid Indonesianit Italianja Japaneseko Koreanmk Macedonianpl Polishpt Portuguesero Romanianru Russiansr Serbiansk Slovaksl Slovenianes Spanishsv Swedishth Thaitr Turkishvi Vietnamese

News

Recognising excellence in CML - Congratulations to the 2025 iCMLf prize winners

2025 iCMLf Prize winnersMarch 2025 - Every year, the iCMLf Prizes acknowledge individuals whose remarkable contributions have shaped the field of CML, driving progress in research, treatment, and care worldwide. This year, we celebrate three outstanding people whose work has transformed our understanding of CML biology, refined clinical management, and improved CML treatment and care in low- and middle-income countries.

We are delighted to announce the recipients of the 2025 iCMLf Prizes:

  • Rowley Prize – Professor Satu Mustjoki (Finland)
  • Goldman Prize – Dr. Delphine Rea (France)
  • iCMLf Prize – Professor Nicholas Anthony Othieno-Abinya (Kenya)

25 Years of TKIs: A Timeline of Transformation


TKIs logo ideasTwenty-five years ago, the landscape of chronic myeloid leukemia (CML) treatment changed forever with the introduction of tyrosine kinase inhibitors (TKIs). Before this breakthrough, CML was a life-threatening diagnosis, with limited treatment options such as interferon therapy or bone marrow transplantation. Today, thanks to TKIs, CML has transformed into a manageable condition, allowing patients to live full and productive lives.

Register Now: iCMLf Regional Discussion Groups - South Asia 2025

We are pleased to announce the first instalment of our 2025 South Asian regional program to address specific local challenges for physicians treating people with CML. We are starting this year's progam of three zoom-based Regional Discussion Groups on April 23rd.

Register Now: iCMLf Regional Discussion Groups - Latin America 2025

We are pleased to announce the first instalment of our 2025 Latin American regional program to address specific local challenges for physicians treating people with CML. We are starting this year's progam of three zoom-based Regional Discussion Groups on May 8th.

iCMLf Launches Climb for a Cure 2026: Conquer the Avenue of Volcanoes to Transform CML Care

Are you ready for an unforgettable adventure that makes a difference?Climb26Logo

Building on the success of Climb for a Cure: Kilimanjaro (2019) and Annapurna (2023) - which together raised over $500,000 for CML research - the iCMLf is thrilled to announce the next chapter: Climb for a Cure 2026.

In February 2026, we will take on the Avenue of Volcanoes in Ecuador - a breathtaking high-altitude challenge through one of the most stunning landscapes in the world. Over seven days, participants will trek through Cotopaxi National Park, climb to awe-inspiring viewpoints, and push their limits alongside a passionate team of researchers, doctors, patients, and CML advocates - all united by a single goal: drive progress in CML research, treatment, and patient care.

Share your experiences - Hepatitis B and CML survey open until February 27th

Hepatitis B website bannerFebuary 2025 - It’s still time to share your experiences in the iCMLf Hepatitis B Virus (HBV) and CML Screening and Management Survey. Your input is invaluable, and we look forward to learning from your clinical practice.

This survey is a key initiative to address the risk of HBV reactivation in CML patients receiving TKI therapy. Since there are currently no comprehensive guidelines and recommendations on HBV screening and monitoring for CML patients on TKIs, the data collected will help bridge this gap and inform future recommendations.

Submissions are welcome until February 27th, 2025.